Desirable Lipoprotein Parameters in Early Drug Trials
Lipid-lowering drugs may be tested very early in patients, in view of the overall “normality” of these subjects, aside from their specific biochemical disorder. Although current modalities for the early evaluation of new drug products require administration to “healthy” volunteers, it is becoming more and more common to carry out early testing in “healthy” subjects with elevated plasma lipid levels. In view of the high expectation for new drug products, active in primary hyperlipoproteinemias (The Lipid Research Clinics 1984), we personally consider as feasible and advisable to carry out the Phase I evaluation of new drugs for hyperlipidemia in patients. These should possibly never have received drug treatments or, in some cases, should be evaluated after stopping treatment with specific products (e.g. anion-binding resins).
KeywordsCholesterol Corn Lipase Heparin Dextran
Unable to display preview. Download preview PDF.
- Baggio G, Briani G, Fellin R, et al. (1979) Effect of tiadenol on the concentration and composition of serum lipoproteins in familial hypercholesterolemia. Artery 5:486–498Google Scholar
- Eisenberg S (1985) High density lipoprotein metabolism. J Lipid Res 25:1017–1058Google Scholar
- Gidez LI, Miller GJ, Burstein M, Eder HA (1979) Analysis of plasma HDL subclasses by a precipitation procedure. In: Rep HDL Methodology Worksh, NIH Publ 82–1661, Bethesda, MD, p 328Google Scholar
- Mattson FM, Grundy SM (1985) Comparison of effects of dietary saturated, monounsaturated and polyunsaturated fatty acids on plasma lipids and lipoproteins in man. J Lipid Res 26:199–202Google Scholar
- Pan HY, Willard DA, Funker PT, McKinstry DN (1986) The clinical pharmacology of SQ 31,000 (CS-514) in healthy subjects. IX Int Symp Drugs Affecting Lipid Metabolism. Florence, Italy, October 22–25Google Scholar
- Sirtori CR, Franceschini G (1984) Drug effects on HDL. In: Miller NE, Miller GJ (eds) Clinical and metabolic aspects of high-density lipoproteins. Elsevier, Amsterdam, p 341Google Scholar
- Sirtori CR, Franceschini G, Gianfranceschi G, et al. (1987) Effects of gemfibrozil on plasma lipoprotein/apolipoprotein distribution and platelet reactivity in hypertriglyceridemic patients. J Lab din Med (in press)Google Scholar